Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Market Cap	16.04B +30.6%
Revenue (ttm)	898.10M +121.7%
Net Income	-67.50M
EPS	-0.08
Shares Out	883.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,992,783
Average Volume	44,751,028
Open	18.83
Previous Close	18.16
Day's Range	18.13 - 18.83
52-Week Range	10.50 - 31.19
Beta	0.92
RSI	37.90
Earnings Date	Apr 25, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermedia...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,035
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300199

Financial Performance

In 2024, Hybio Pharmaceutical's revenue was 590.20 million, an increase of 36.82% compared to the previous year's 431.38 million. Losses were -173.65 million, -66.21% less than in 2023.